BBIO Stock Overview
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.
BridgeBio Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.24|
|52 Week High||US$65.33|
|52 Week Low||US$4.98|
|1 Month Change||27.62%|
|3 Month Change||-11.41%|
|1 Year Change||-84.71%|
|3 Year Change||-65.74%|
|5 Year Change||n/a|
|Change since IPO||-66.46%|
Recent News & Updates
BridgeBio Pharma: Yet To Be Proven Business Model
BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked. It does have a lot of cash.
News Flash: Analysts Just Made A Dazzling Upgrade To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Forecasts
BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders will have a reason to smile today, with the analysts making...
|BBIO||US Biotechs||US Market|
Return vs Industry: BBIO underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: BBIO underperformed the US Market which returned -18.4% over the past year.
|BBIO Average Weekly Movement||16.4%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: BBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: BBIO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
BridgeBio Pharma Fundamentals Summary
|BBIO fundamental statistics|
Is BBIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BBIO income statement (TTM)|
|Cost of Revenue||US$4.46m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.03|
|Net Profit Margin||-839.85%|
How did BBIO perform over the long term?See historical performance and comparison
Is BBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BBIO?
Other financial metrics that can be useful for relative valuation.
|What is BBIO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BBIO's PS Ratio compare to its peers?
|BBIO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
XENE Xenon Pharmaceuticals
SAGE Sage Therapeutics
BBIO BridgeBio Pharma
Price-To-Sales vs Peers: BBIO is good value based on its Price-To-Sales Ratio (19.2x) compared to the peer average (101.1x).
Price to Earnings Ratio vs Industry
How does BBIO's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: BBIO is expensive based on its Price-To-Sales Ratio (19.2x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is BBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||19.2x|
|Fair PS Ratio||45.1x|
Price-To-Sales vs Fair Ratio: BBIO is good value based on its Price-To-Sales Ratio (19.2x) compared to the estimated Fair Price-To-Sales Ratio (45.1x).
Share Price vs Fair Value
What is the Fair Price of BBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BBIO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BBIO's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BBIO's PEG Ratio to determine if it is good value.
Discover undervalued companies
- Take a look at our analysis of BBIO's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How is BridgeBio Pharma forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BBIO's revenue (50.4% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: BBIO's revenue (50.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BBIO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has BridgeBio Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BBIO is currently unprofitable.
Growing Profit Margin: BBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BBIO is unprofitable, and losses have increased over the past 5 years at a rate of 41.8% per year.
Accelerating Growth: Unable to compare BBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: BBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is BridgeBio Pharma's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BBIO has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BBIO has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 38.4% each year.
Discover healthy companies
What is BridgeBio Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BBIO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BBIO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Neil Kumar (42 yo)
Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder and serves as Chief Executive Officer and Director BridgeBio Pharma, Inc. since April 2015 and serves as President...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD25.63M) is above average for companies of similar size in the US market ($USD5.47M).
Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.
Experienced Management: BBIO's management team is considered experienced (3.7 years average tenure).
Experienced Board: BBIO's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BridgeBio Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: BridgeBio Pharma, Inc.
- Ticker: BBIO
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.365b
- Shares outstanding: 147.69m
- Website: https://www.bridgebio.com
Number of Employees
- BridgeBio Pharma, Inc.
- 421 Kipling Street
- Palo Alto
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.